Photodynamic Therapy for the Treatment of Glioblastoma

Samuel W. Cramer, Clark C. Chen

Research output: Contribution to journalReview articlepeer-review

49 Scopus citations

Abstract

Glioblastoma is the most common form of adult brain cancer and remains one of the deadliest of human cancers. The current standard-of-care involves maximal tumor resection followed by treatment with concurrent radiation therapy and the chemotherapy temozolomide. Recurrence after this therapy is nearly universal within 2 years of diagnosis. Notably, >80% of recurrence is found in the region adjacent to the resection cavity. The need for improved local control in this region, thus remains unmet. The FDA approval of 5-aminolevulinic acid (5-ALA) for fluorescence guided glioblastoma resection renewed interests in leveraging this agent as a means to administer photodynamic therapy (PDT). Here we review the general principles of PDT as well as the available literature on PDT as a glioblastoma therapeutic platform.

Original languageEnglish (US)
Article number81
JournalFrontiers in Surgery
Volume6
DOIs
StatePublished - Jan 21 2020

Bibliographical note

Publisher Copyright:
© Copyright © 2020 Cramer and Chen.

Keywords

  • brain tumor
  • glioblastoma multiforme (GBM)
  • neurosurgery
  • photodynamic therapy (PDT)
  • tumor-targeting

PubMed: MeSH publication types

  • Review
  • Journal Article

Fingerprint

Dive into the research topics of 'Photodynamic Therapy for the Treatment of Glioblastoma'. Together they form a unique fingerprint.

Cite this